MIRM
Mirum Pharmaceuticals, Inc.
MIRM lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
MIRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Weak |
MIRM's revenue is currently healthy, but its profitability, cash flow and balance sheet are weak.
MIRM PE Valuation
MIRM has no meaningful PE right now: it lost money over the past year.
MIRM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect MIRM's losses to grow, with revenue growing. However, they disagree widely on these estimates.
MIRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.46 | -$14.60 |
| Q2 2026 | -$14.54 | -$13.33 |
| Q1 2026 | -$13.60 | -$11.99 |
| Q4 2025 | -$0.47 | +$1.38 |
| Q3 2025 | -$0.86 | +$1.19 |
| Q2 2025 | -$1.21 | +$1.11 |
| Q1 2025 | -$1.61 | +$2.13 |
| Q4 2024 | -$1.85 | +$2.15 |
MIRM lost $15.46 per share over the past year, and its loss has widened in each of the last three quarters.
MIRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $185.7M | +40% |
| Q2 2026 | $176.2M | +38% |
| Q1 2026 | $159.9M | +43% |
| Q4 2025 | $148.9M | +50% |
| Q3 2025 | $133M | +47% |
| Q2 2025 | $127.8M | +64% |
| Q1 2025 | $111.6M | +61% |
| Q4 2024 | $99.4M | +43% |
MIRM's revenue has grown year over year every quarter since mid-2022: $186M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -32% | -34 points |
| Q2 2026 | -24% | -20 points |
| Q1 2026 | -494% | -480 points |
| Q4 2025 | -3.1% | +21 points |
| Q3 2025 | 2% | +16 points |
| Q2 2025 | -3.9% | +27 points |
| Q1 2025 | -14% | +25 points |
| Q4 2024 | -24% | +23 points |
MIRM's operating margin was −32% last quarter, down 34 points from the same quarter a year ago.
MIRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.6M | -114% |
| Q2 2026 | -$44.3M | -472% |
| Q1 2026 | -$229.4M | -$227.4M |
| Q4 2025 | $5.5M | +$10.6M |
| Q3 2025 | $39.5M | +938% |
| Q2 2025 | $11.9M | +$16.5M |
| Q1 2025 | -$2M | -113% |
| Q4 2024 | -$5.1M | +$11.5M |
MIRM has burned cash in most quarters: −$274M over the past year, against $44M the year before.
MIRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.2% | +2.7M shares |
| 1 year | +16% | +9.1M shares |
| 3 years | +61% | +25M shares |
| 5 years | +117% | +35.7M shares |
| Available history | +167% | +41.3M shares |
MIRM has 66M diluted shares, up 16% from a year ago.
MIRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 6.2x | High |
MIRM's net debt is about 6.2 years of its operating earnings (EBITDA).
MIRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.3 | Neutral |
| Stochastic | 43.7 | Neutral |
MIRM's weekly RSI is 49 (neutral) and its Stochastic is 44 (neutral).
MIRM PE vs Healthcare Sector
MIRM has no meaningful PE right now: it lost money over the past year.
MIRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $86.4 | 8% above |
| 20 week MA | $98.1 | 4.9% below |
| 50 week MA | $95.4 | 2.2% below |
| 100 week MA | $75.2 | 24% above |
| 200 week MA | $52.8 | 77% above |
MIRM's trend is mixed: it's above three of its five weekly moving averages, and 77% above its 200-week average.
MIRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.9 | $18.3 | -30% |
| 2021 | $18.3 | $15.6 | -15% |
| 2022 | $15.6 | $18.2 | +17% |
| 2023 | $18.2 | $29.5 | +62% |
| 2024 | $29.5 | $41.6 | +41% |
| 2025 | $41.6 | $79.3 | +91% |
| 2026 YTD | $79.3 | $93.3 | +18% |
MIRM has finished higher in four of the last six years, two of them by more than 50%. It's up 18% so far in 2026.